Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: 5 - You Need To See This

The Insider Report: Prepare for the Next Dip Buying Opportunity

The turbulence in stocks continued with the Nasdaq reeling from the tech wreck. It finished down 2.74%, while the Dow Jones Industrial Average and the SP 500 finished down 1.91% and 1.94%, respectively. The rotation into healthcare continues to accelerate, and it's really the only sector offering abundant and attractive…

Benzinga

AstraZeneca Calms Pricing Jitters, Says US Deal Hit Absorbable

AstraZeneca Plc (NASDAQ:AZN) on Thursday reported third-quarter 2025 sales of $15.19 billion, up 12% year over year (+10% at constant currency), beating the consensus of $14.80 billion, driven by double-digit growth in oncology, CVRM, and biopharmaceuticals.

Benzinga

NHS won’t get cutting-edge drugs unless it pays more, says AstraZeneca boss

Pascal Soriot calls for cost-effectiveness thresholds to undergo ‘substantial adjustment based on inflation’

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Time for Reeves to recognise reality: AstraZeneca has killed stamp duty on shares

Shareholder-backed plans to upgrade US listing have exposed multiple flaws in tax that should be abolished or at least cut

The Guardian - UK

3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years

Here are three big pharma stocks that can reward patient investors with a proven history of stability, dividends, and long-term growth potential

MarketBeat

Trump’s approach to lowering drug costs is raising questions - Roll Call

Several drug pricing experts say without key details, it’s hard to call the individual pharma deals a win for the Trump administration.

Roll Call

Miners prosper as FTSE 100 makes steady progress

On the FTSE 100, gold miners Fresnillo and Endeavour Mining leapt 9.1% and 11% respectively.

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

Trump Secures Major Win as AstraZeneca Joins Pfizer in Lowering US Drug Prices

AstraZeneca joins Pfizer in cutting US drug prices under Trump's new deal to offer lower costs for Medicaid patients.

International Business Times

Trump's Rx for confusion: How a push for tariffs complicated his pharma plan

The president's road to settling on a plan to lower prescription drug costs was rocky.

Axios

AstraZeneca Joins Trump's Push to Make Medicines Cheaper — But Why Are Critics Skeptical?

US President Donald Trump announced a deal with UK pharmaceutical AstraZeneca to lower certain drugs for government's Medicaid health plan.

International Business Times UK

AstraZeneca makes deal with Trump to lower drug prices and avoid tariffs

Company will sell some medicines at a discount to government’s Medicaid health plan in exchange for tariff relief

The Guardian - US

AstraZeneca agrees to lower drug prices for Medicaid under Trump administration deal

AstraZeneca has agreed to lower prescription drug costs for Medicaid under a deal with the Trump administration

The Independent UK

Trump announces AstraZeneca will offer discount drugs on ‘TrumpRx’ website

TrumpRx.gov, a website where Americans can buy pharmaceutical drugs under President Donald Trump’s new drug pricing plan, is set to begin operation in 2026

The Independent UK

Trump Plans AstraZeneca Deal To Cut Drug Prices For Low-Income Americans

President Donald Trump is reportedly set to announce a new agreement with AstraZeneca Plc (NASDAQ:AZN) designed to reduce prescription drug costs for Americans.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

AstraZeneca Expands Virginia Investment To $4.5 Billion For Cancer, Obesity Drugs

AstraZeneca Plc (NASDAQ:AZN) on Thursday said it will invest $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500 million to support the enhanced manufacturing capability of a broader range of medicines, including cancer treatments.

The Guardian - UK

NHS could pay 25% more for medicines under plan to end row with drugmakers and Trump

UK ministers preparing to raise payments to end standoff with pharma industry, cited as reason for firms axing British investments

Benzinga

AstraZeneca's Baxdrostat Shows Meaningful Blood Pressure Control In Patients With Resistant Hypertension

On Tuesday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Bax24 Phase 3 trial to evaluate the safety, tolerability, and the effect of 2mg baxdrostat versus placebo.

Benzinga

AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases

Algen Biotechnologies, a privately held biotech company specializing in advanced CRISPR gene modulation and AI-driven drug discovery, has announced a multi-target partnership with AstraZeneca Plc (NASDAQ:AZN) to accelerate the discovery of novel therapeutic targets in immunology.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy

AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo on Monday released high-level results from the TROPION-Breast02 Phase 3 trial.

Evening Standard

FTSE 100 hits another high despite concerns over US government shutdown

Drug companies AstraZeneca, Hikma Pharmaceuticals and GSK were all big risers.

The Conversation

The UK must invest in medicines – but not at any price

The UK’s science minister, Sir Patrick Vallance, has sounded the alarm over the country’s declining investment in medicines. He warned that the NHS risks losing out on important treatments and the country could lose its place at the cutting edge of medical research if spending does not recover. It comes…

The Guardian - UK

AstraZeneca’s listing rejig spells long-term danger for London

It’s not skipping off entirely to New York, but pharma giant sets a worrying precedent for UK stock market

Benzinga

AstraZeneca Moves From ADRs To NYSE Listing

The Board of AstraZeneca plc (NASDAQ: AZN) is recommending to shareholders a Harmonized Listing Structure for the company's ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York Stock Exchange (NYSE).

Euronews

AstraZeneca will list shares directly in New York, but isn't leaving the UK

Amid concerns it might leave the UK, the pharma giant reaffirmed its commitment to the country, keeping its headquarters, primary listing, and tax base there.

The Independent UK

Emma Walmsley steps down as CEO of GSK as pharmaceutical industry faces upheaval

The drug and vaccine maker is a £60bn firm – one of the biggest in the UK

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.